Status:
COMPLETED
Extension Program for Bay 43-9006
Lead Sponsor:
Bayer
Conditions:
Neoplasm
Metastasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-...
Eligibility Criteria
Inclusion
- Patients who had participated in a previous sorafenib study that had completed, who did not meet withdrawal criteria of the previous study and who were, in the opinion of the investigator and sponsor still benefiting from treatment.
Exclusion
- The current cardiovascular situation of the patient was carefully re-evaluated by both the investigator and the sponsor and an informed decision as to inclusion was then made.- Substance abuse, medical, psychological or social conditions that may have interfered with the patient's participation in the study or evaluation of the study results.- Known or suspected allergy to the investigational agent.- Any condition that was unstable or which could jeopardise the safety of the patient and his/her compliance in the study.
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00657254
Start Date
December 1 2002
End Date
June 1 2005
Last Update
December 23 2014
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston, Massachusetts, United States, 02115-6084
2
Bruxelles - Brussel, Belgium, 1000
3
Hamilton, Ontario, Canada, L8V 5C2
4
Toronto, Ontario, Canada, M5G 2M9